Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chemotherapy
U.S. FDA approves EMEND for the prevention of nausea and vomiting associated with chemotherapy
February 8th, 2006
Merck & Co., Inc., announced that the U.S. Food & Drug Administration (FDA) has approved EMEND (aprepitant) for use with other antiemetic medicines for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, which are likely to cause nausea and vomiting. EMEND, in combination with other antiemetics, is also approved for the prevention of nausea and vomiting caused by initial and repeat courses of highly emetogenic chemotherapy treatments, which are highly likely to cause nausea and vomiting, including high dose cisplatin. The FDA approval for EMEND is based on the findings of a study...
Source: Immunotherapy Weekly (2006-02-08)
|
